PDL1 targeted antisense oligonucleotide therapeutic - Secarna Pharmaceuticals
Alternative Names: PDL1 antisense oligonucleotide - Secarna PharmaceuticalsLatest Information Update: 28 Mar 2025
At a glance
- Originator Secarna Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Gene silencing; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Cancer in Germany
- 20 Dec 2023 Pharmacodynamics data from a preclinical trial in Cancer released by Secarna Pharmaceuticals (Secarna Pharmaceuticals pipeline, December 2023)
- 31 Mar 2023 Preclinical development is ongoing Germany (Secarna Pharmaceuticals pipeline, March 2023)